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Hepatitis C is a viral infection that leads to chronic liver disease 
resulting in significant morbidity and mortality, with many patients 
progressing to liver cirrhosis and hepatocellular carcinoma. It tops 
the list of indications for liver transplantation in Japan, Europe and 
the USA.[1] Seven major hepatitis C virus (HCV) genotypes have been 
recognised since the identification of HCV in 1989. These genotypes 
are one of the most critical factors determining response to therapy. [2] 
Genotype 5 is reported to be the predominant HCV genotype in 
South Africa (SA), constituting ~40% of HCV infections, followed by 
genotype 1 (33%).[3]
Risk factors for hepatitis C infection include blood and blood 
products transfusion and organ transplantation prior to 1992, 
intravenous drug use, long-term haemodialysis, multiple sexual 
partners, tattooing and scarification, unsafe medical practices, 
HIV infection, and being born to an HCV-infected mother.[4-7] 
Interestingly, the ethnic background of patients has also been 
reported to determine the prevalence of HCV infection. A US study 
including >5 million individuals reported the highest prevalence of 
hepatitis C in blacks, followed by Hispanics.[8]
Anti-HCV antibodies are used for screening for hepatitis C. 
Thereafter qualitative and quantitative assays are used to detect the 
HCV virus RNA and determine the number of existing viral copies. 
Further tests are done to determine the genotypes and their subtypes.
Patients diagnosed with hepatitis C usually require a liver biopsy 
before starting treatment unless contraindicated, e.g. patients with 
thrombocytopenia and haemophilia. Liver biopsy is done to assess 
the degree of fibrosis and detect other liver disorders such as fatty 
liver and iron overload. According to the 2010 SA hepatitis C 
guidelines,[9] liver biopsy was not mandatory in HCV genotypes 
2 and 3 because of excellent sustained viral response (SVR) rates 
(90%) with the combination of pegylated interferon and ribavirin 
(PEG-RBV) in those individuals.[9] The METAVIR score is usually 
used to report on the liver histology.[10] Recently, non-invasive scores 
have been introduced as predictors of liver fibrosis. These include 
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Background. Hepatitis C is a viral infection that leads to chronic liver disease, resulting in significant morbidity and mortality.
Objectives. To describe the demographic characteristics and clinical presentation of patients with chronic hepatitis C infection. The aspartate 
aminotransferase-to-platelet ratio index (APRI) and the fibrosis index based on 4 factors (FIB-4) were assessed for prediction of liver fibrosis.
Methods. We retrospectively reviewed 87 records of patients who presented to the liver clinic at Chris Hani Baragwanath Academic 
Hospital, Johannesburg, South Africa, from January 2007 to December 2016. Patients’ records were reviewed and analysed using SPSS 
statistical software version 24. Convenience sampling was used.
Results. The patients’ mean (standard deviation (SD)) age was 52.6 (12.3) years. Fifty-four percent were female. Hepatitis C virus genotype 
5 was exclusively found in blacks (p<0.001), constituting 60.3% of infections in this ethnic group and 48.7% in the cohort, followed by 
genotype 1 (21.8%), genotype 3 (15.4%), genotype 4 (10.3%) and mixed-genotype infections (3.8%). Genotype 5 patients were older (mean 
(SD) age 56.7 (9.8) years) than genotype 1 (46.3 (11.4) years) and genotype 3 (42 (9.8) years) (p=0.002 and p<0.001, respectively). The 
receiver operating characteristic curve for METAVIR F0 v. APRI (cut-off <0.7) showed a moderate correlation, with an area under the curve 
(AUC) of 0.349 (p=0.002), sensitivity of 78.8%, specificity of 70.6% and a negative predictive value (NPV) of 63.2%. METAVIR F4 v. APRI 
(cut-off ≥1.5) showed an AUC of 0.881 (p=0.001) with sensitivity of 85.7%, specificity of 93% and a positive predictive value (PPV) of 67%. 
METAVIR F0 v. FIB-4 (cut-off <1.45) showed a moderate correlation, with an AUC of 0.332 (p=0.021), sensitivity of 78.3%, specificity of 
53.8% and an NPV of 73.7%. METAVIR F4 v. FIB-4 (cut-off >3.25) had a strong correlation, with an AUC of 0.952 (p<0.001), sensitivity of 
63.6%, specificity of 100% and a PPV of 100%. Early virological response (EVR) was found to predict sustained virological response (SVR) 
to therapy (odds ratio 27.8; 95% confidence interval 2.8 - 274.3; p=0.004).
Conclusions. Compared with other genotypes, genotype 5 was predominant in our cohort, particularly in older age groups. Moreover, APRI 
and FIB-4 scores correlated significantly with advanced fibrosis in HCV patients. Finally, EVR during therapy was found to determine SVR.
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the aspartate aminotransferase-to-platelet ratio index (APRI) and 
the fibrosis index based on four factors (FIB-4).[11,12] The APRI 
and FIB-4 scores have been reported to identify hepatitis C-related 
fibrosis in many studies, thus alleviating the need for the invasive 
liver biopsy. [10,13,14] Sonderup et al.[15] emphasised the importance 
of these scores in the assessment of liver fibrosis in the context of 
hepatitis C in sub-Saharan Africa, as they are cheap, available, easy 
to interpret and can be done in an outpatient setting. However, these 
scores have not been reported on in HCV-infected individuals in SA 
or sub-Saharan Africa.
Other useful non-invasive methods for evaluation of liver fibrosis/
cirrhosis include computed tomography liver surface nodularity 
scores, magnetic resonance elastography, and transient elastography 
(FibroScan).[16] Lack of expertise and the high cost of these methods 
prevent their regular use. FibroScan uses measurement of liver 
stiffness to detect cirrhosis. While it is an excellent tool for assessment 
of liver cirrhosis, it is not readily available, especially in low-income 
settings.[17]
The standard treatment used for chronically infected patients 
with hepatitis C in SA was the combination of PEG-RBV for 24 or 
48 weeks, with SVR achieved in up to 80% of those treated.[18] How-
ever, achievement of an SVR is governed by the HCV genotype along 
with other factors such as genetic factors, e.g. interleukin (IL)-28B.[10,19] 
Hadziyannis et al.[20] showed that patients infected with genotype 1 need 
standard doses of ribavirin, while those infected with genotypes 2 and 3 
are adequately treated with low doses. Given the serious side-effects of 
such a combination[21] and obstacles to its use among large numbers of 
HCV patients, deciding whether to use the combination was not always 
easy.[22] Since the introduction of directly acting antivirals (DAAs) in 
May 2011, hepatitis C treatment has evolved tremendously, especially 
with the introduction of pangenotypic regimens that conferred higher 
SVR rates with shorter duration of therapy.
Several factors are known to predict response to HCV therapy, 
including: (i) age, with age <40 years associated with a better 
response; (ii) race (whites do better than blacks in US studies); 
(iii) body mass index (BMI) (patients with a BMI <25 kg/m2 do better 
than those with higher BMIs); (iv) HCV genotype; (v) viral load; 
(vi)  rapid viral response; and (vii) the degree of liver fibrosis, and 
alpha-fetoprotein and IL-28B gene polymorphism.[23]
Objectives
Despite the impact of HCV infection on the SA population, especially 
in view of its frequent coexistence with the highly prevalent HIV 
infection, there is a lack of published data on HCV. This study 
therefore aimed to describe the demographic characteristics of 
patients with chronic hepatitis C, disease presentation, clinical 
parameters, co-infection with hepatitis B and HIV, and response 
to therapy. It also aimed to assess the utility of the fibrosis score in 
detecting liver fibrosis. It is expected that the findings will help to 
provide data on the spectrum of hepatitis C infection in a referral 
hospital setting in SA and to shed light on the use of fibrosis scores 
in the SA setting.
Methods
The research protocol was approved by the Human Research Ethics 
Committee of the University of the Witwatersrand (ref. no. M170538).
Study population
We retrospectively reviewed 87 records of patients who presented 
to the liver clinic in the Division of Gastroenterology at Chris Hani 
Baragwanath Hospital (CHBAH), Johannesburg, between January 
2007 and December 2016. No files were excluded. Patients diagnosed 
with hepatitis C infection were referred from local clinics, the South 
African National Blood Service, CHBAH and private clinics. Their 
records were reviewed and analysed. Convenience sampling was 
used.
The datasets used and/or analysed during the study are available 
from the corresponding author (WBA) on reasonable request.
Data collection
A standardised data collection sheet was used. Data were extracted 
from records of all patients who attended the clinic. The results of 
baseline investigations, including a full blood count, liver function 
tests, urea and electrolytes, hepatitis C viral load and genotype, 
hepatitis B serology and HIV serology, were recorded. Liver biopsy 
results, where available, were extracted. A liver biopsy was performed 
in all consenting patients except where it was contraindicated or 
was not part of the treatment protocol (it was not done in patients 
with genotype 3). Patients eligible for treatment were treated with 
PEG-RBV. Hepatitis C viral load levels measured during treatment 
and at 24 weeks after treatment completion to determine SVR were 
extracted.
Definitions
Treated patients were deemed to have achieved a rapid virological 
response if they had an undetectable HCV viral load at week 4 of 
therapy. Early virological response (EVR) was defined as complete 
when viral load was undetectable at 12 weeks of treatment or as 
partial when there was a 2-log drop in viral load at 12 weeks of 
treatment. SVR was defined as an undetectable HCV viral load 24 
weeks after completion of treatment.
Statistical analysis
All data were analysed using SPSS statistical software, version 24.0 for 
Windows (SPSS Inc., USA). Categorical data such as gender, ethnicity 
and symptoms were analysed using Pearson’s χ2 test or Fisher’s exact 
test when >20% of cells had an expected frequency <5. Continuous 
data such as age and viral load were analysed using parametric 
methods and presented as means and standard deviations (SDs) 
or medians and percentiles for non-normally distributed data. The 
geometric mean was used to analyse BMI and viral load. The t-test 
was used in the analysis of normally distributed continuous data, and 
one-way analysis of variance with Dunett’s correction was used to 
compare the ages of patients with the different genotypes; otherwise 
the Mann-Whitney U-test was used. Multinomial logistic regression 
was used to determine the risk factors for HCV infection in the 
study cohort after calculating their univariate logistic regression. The 
Wilcoxon signed-rank test was used for analysis of treatment effect 
on viral load and liver enzymes. Eta correlation was used to assess 
the correlation between the METAVIR, APRI and FIB-4 scores, while 
Spearman’s correlation was used for the correlation between APRI 
and FIB-4 scores. The receiver operating characteristic (ROC) curve 
was also used to compare APRI and FIB-4 with the gold standard 
METAVIR. A p-value of <0.05 was considered statistically significant.
Results
Demographics
Eighty-seven patients’ records were identified (Fig. 1). The mean 
(SD) age of the cohort at presentation was 52.6 (12.3) years. Female 
patients constituted 53.5% of the group. There were 71 blacks 
(81.7%), 9 Asians (10.3%) and 7 whites (8.0%). Black HCV-infected 
patients tended to be older compared with other ethnic groups, with a 
mean (SD) age of 55.7 (10.6) years, which was statistically significant 
(p=0.001) (Table 1).
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Risk factors
Twenty-three of the black patients had a history of blood transfusion, 
but this was not statistically significant. Five individuals had 
haemophilia. There was no statistically significant difference in the 
prevalence of haemophilia between the different ethnic groups. 
White patients had more tattooing and history of intravenous 
drug use than blacks and Asians, which was statistically significant 
(p<0.001) (Table 1). Histories of previous surgery and scarification 
were not significantly different between the ethnic groups. Data for 
men who have sex with men were not available.
Clinical presentation
Thirty-one patients (35.6%) were incidentally diagnosed. Forty-seven 
(60.3%) were symptomatic. In 9 patients (10.3%), presentation was 
Table 1. Hepatitis C infection: Cohort characteristics according to ethnicity
                                                          Ethnicity
Characteristics Black (N=71) White (N=7) Asian (N=9)
Age (years), mean (SD) 55.7 (10.6) 33.1 (3.9) 43.6 (11.6)
Gender, n (%)
Male 33 (46.5) 3 (42.9) 4 (44.4)
Female 38 (53.5) 4 (57.1) 5 (55.6)
Comorbidities, n (%)
DM 8 (11.3) 0 2 (22.2)
CKD 8 (11.3) 0 0
Haemophilia 4 (5.65) 1 (14.3) 0
Chronic hepatitis B 2 (2.83) 0 1 (11.1)
HIV 16 (22.6) 1 (14.3) 0
BMI, mean (SD) 25.1 (1.2) 24 (1.2) 26.3 (1.15)
Risk factors, n (%)
Blood transfusion 23 (32.4) 1 (14.3) 2 (22.2)
Tattoo 0 3 (42.9) 0
Scarification 1 (1.4) 0 0
IV drug use 0 3 (42.9) 0
Surgery 11 (15.5) 0 2 (22.2)
GTs (N=78), n (%) 63 (80.8) 6 (7.7) 9 (11.5)
GT 1 11 (17.5) 2 (33.3) 4 (44.4)
GT 3 3 (4.8) 4 (66.6) 5 (55.6)
GT 4 8 (12.7) 0 0
GT 5 38 (60.3) 0 0
>1 GT 3 (4.8) 0 0
VL, mean (SD) Log 5.8 (0.8) Log 5.6 (1.2) Log 5.5 (1.2)
Total treated (N=48), n (%) 37 (52.1) 5 (71.4) 6 (66.7)
Response/non-response to treatment, N 34 5 5
SVR, n (%) 27 (79.4) 5 (100) 2 (40.0)
Non-responders, n (%) 5 (14.7) 0 2 (40.0)
Relapse, n (%) 2 (5.9) 0 1 (20.0)
SD = standard deviation; DM = diabetes mellitus; CKD = chronic kidney disease; BMI = body mass index; IV = intravenous; GT = genotype; VL = viral load; SVR = sustained virological response.












































Fig. 1. Flow chart of the study cohort. (SVR = sustained virological response.)
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not documented. Of symptoms and signs, 
the most frequent was joint pain (n=11; 
12.8%). This was followed in frequency 
by ascites (n=6; 6.9%), lower limb oedema 
(n=5; 5.7%) and jaundice (n=5; 5.7%). Of 
the 78 patients for whom the information 
was available, 9 were smokers; 13/81 patients 
consumed alcohol. The geometric mean 
(SD) BMI was 25.12 (1.2).
Comorbidities
Comorbidities in this cohort included 
diabetes mellitus (n=10 patients), chronic 
kidney disease (n=8 black patients) and 
cardiovascular disease (n=7). There was 
no statistically significant difference in the 
prevalence of comorbidities between the 
different ethnic groups. Of the 87 patients, 3 
(2 blacks and 1 Asian) had chronic hepatitis 
B, while 17 patients had HIV infection 
(n=16 (22.5%) black and n=1 (14.3%) white 
patients). The median (interquartile range) 
CD4+ count for the HIV co-infected patients 
was 448 (283 - 900) cells/µL.
Genotypes
Genotypes were available for 78 patients. 
Genotype 5 was exclusively found in blacks. 
It constituted 60.3% of infections in this 
ethnic group and 48.7% in the cohort, 
followed by genotype 1 (21.8%), genotype 
3 (15.4%), genotype 4 (10.3%) and mixed-
genotype infection (3.8%). When genotype 
5 was compared with HCV genotypes in 
other ethnic groups, a statistically significant 
difference was evident (p<0.001). Genotype 
5 patients were found to be older, with a 
mean (SD) age of 56.7 (9.8) years, compared 
with genotype 1 (46.3 (11.4) years) and 
genotype 3 (42 (9.8) years) (p=0.002 and 
p<0.001, respectively).
Viral loads
The mean (SD) viral load for the cohort 
was log 5.7 (0.9). There was no statistical 
difference between the different ethnic 
groups or different genotypes in terms of 
viral load levels.
METAVIR and fibrosis scores
Fifty-nine patients, of whom 10 were known 
to be HIV-positive, had liver biopsy results. 
The mean (SD) platelet count for patients 
with HIV was 297 (92) × 109/L. Metavir and 
APRI scores and FIB-4 and APRI scores 
were found to be strongly correlated (r=1, 
0.997 and 0.817, respectively). The ROC 
curve for METAVIR F0 and APRI (cut-off 
<0.7) showed a moderate correlation, with 
an AUC of 0.349 (p=0.002), sensitivity of 
78.8%, specificity of 70.6% and a negative 
predictive value (NPV) of 63.2%, and that 
for METAVIR F4 v. APRI (cut-off ≥1.5) had 
an AUC of 0.881 (p=0.001) with sensitivity 
of 85.7%, specificity of 93% and a positive 
predictive value (PPV) of 67% (Fig. 2). 
METAVIR F0 v. FIB-4 (cut-off <1.45) had a 
moderate correlation, with an AUC of 0.332 
(p=0.021), sensitivity of 78.3%, specificity 
of 53.8% and an NPV of 73.7%. METAVIR 
F4 v. FIB-4 (cut-off >3.25) had a strong 
correlation, with an AUC of 0.952 (p<0.001), 
sensitivity of 63.6%, specificity of 100% and 
a PPV of 100% (Fig. 3).
Treatment
All treated patients received pegylated 
interferon α-2a (Pegasys) and ribavirin. Of 
48 patients who were treated, 44 completed 
treatment; 34 patients achieved SVR while 
9 did not, and in 1 case results were not 
available (Fig. 1). All but 1 of the patients 
developed side-effects secondary to treat-
ment. Anaemia was the most common 
side-effect (n=33; 68.8%), followed by 
leukopenia (n=31; 65%) and fatigue (n=27; 
56.2%). Growth factors (erythropoietin and 
granulocyte-colony stimulating factor) were 
used in 17 (35.4%) and 6 (12.5%) patients, 
respectively, during treatment.
Both alanine aminotransferase and 
aspartate aminotransferase showed a statisti-
cally significant decline post treatment 
(p<0.001). EVR was found to predict SVR 
to therapy (odds ratio 27.8; 95% confidence 
interval 2.8 - 274.3; p=0.004) (Table 2).
Discussion
Chronic HCV infection causes significant 
morbidity and mortality, as it remains 
asymptomatic for prolonged periods of time 
until the individual develops chronic liver 
disease and/or HCC, yet it is potentially 
curable.[2]
As HCV has the same mode of trans-
mission as HIV, and the prevalence of HIV 
in SA is high, SA would be expected to 
have a large burden of patients with HCV 
infection. There is a paucity of data on HCV 
infection in SA. We describe the clinical 
characteristics of our cohort of 87 patients, 
with specific emphasis on genotype 5. This 
genotype is endemic in SA, but there is 
a paucity of literature on it worldwide. [24] 
Genotype 5 was seen in 48.7% of the patients 
in our cohort; this is similar to what Smuts 
et al.[3] described in a sample of 79 patients. 
On the other hand, Prabdial-Sing et al.[24] 
described a slightly lower proportion of 
genotype 5 infections (36%) in a larger 
cohort studied at the National Health 
Laboratory Service. Ethnic groups were not 
identified in their study. In the present study, 
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Fig. 2. ROC curve showing correlation between APRI and METAVIR scores. (ROC = receiver operating characteristic; APRI = aspartate aminotransferase-
to-platelet ratio index; AUC = area under the curve; NPV = negative predictive value; PPV = positive predictive value.)
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blacks. This could possibly be attributed 
to segregation of racial groups under the 
previous apartheid regime, particularly as 
patients infected with genotype 5 were 
found to be significantly older than those 
with genotypes 1 and 3. The observation 
that genotype 5-infected patients were older 
was also made by French researchers in 
2004.[25] Genotypes 1, 3 and 4 and mixed-
genotype infections followed genotype 5 
in frequency, with percentages of 21.8%, 
15.4%, 10.3% and 3.8%, respectively, 
a distribution similar to that described 
by Prabdial-Sing et al.,[24] who reported 
prevalences of 22% for genotype 1b, 11.7% 
for genotype 3a and 8.91% for genotype 4, 
while the prevalence of mixed infections 
was 7%. On the other hand, these figures 
are much higher than those reported by 
Smuts et al.[3] although the sample sizes were 
not dissimilar.
Rates of hepatitis B infection were low 
in our cohort, despite the shared modes of 
transmission of those infections with HCV 
while slightly more than a fifth of patients 
had HIV co-infection.
Many guidelines on hepatitis C treatment 
recommend assessment of liver fibrosis/
cirrhosis before initiation of therapy.[9,15] 
While liver biopsy has been deemed the 
gold standard, implementing it in all settings 
can be difficult owing to high cost, lack 
of expertise and cultural unacceptability. [15] 
Several non-invasive methods of liver 
fibrosis assessment have been studied and 
developed. These include the APRI and FIB-
4, which have not been studied previously 
in our setting. In our cohort, scores for 
liver fibrosis such as the APRI and FIB-4 
correlated significantly with an advanced 
METAVIR score of fibrosis (METAVIR F3 
and F4). Similar results have been reported 
by others.[13,14] Implementing these scores 
in clinical practice can reduce the need 
for invasive liver biopsies. Interestingly, the 
same fibrosis scores have been found to 
have limitations when used in hepatitis B 
patients. Conventional cut-offs for these 
scores cannot be used to detect cirrhosis 
in the setting of hepatitis B, owing to high 
misclassification rates.[26,27]
Various factors have been found to affect 
clearance of the virus, but in our cohort week 
12 EVR was the only predictor of SVR. Rao 
et al.[18] came to a similar conclusion in their 
multicentre study that included 125 chronic 
hepatitis C patients.
Study strengths and limitations
The major strength of this study is that it 
adds significant information on the clinical 
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Fig. 3. ROC curve showing correlation between FIB-4 and METAVIR scores. (ROC = receiver operating 
characteristic; FIB-4 = fibrosis index based on 4 factors; AUC = area under the curve; NPV = negative 
predictive value; PPV = positive predictive value.)
Table 2. Predictors of SVR
Variables SVR No SVR p-value
Age (years), mean (SD) 47.2 (11.8) 54.7 (9.9) 0.103
Gender, n 0.889
Male (N=19) 15 4
Female (N=24) 18 6 
Ethnicity, n 0.090
White (N=5) 5 0
Black (N=34) 27 7
Asian (N=4) 2 2
HIV (N=4), n 4 0 0.999
GTs, n 0.079




>1 GT 3 0
RVR (N=27), n 23 4 0.211
EVR week 12 (N=43), n 34 9 0.004*
FIB-4 (N=40), n 33 7 0.036
APRI (N=40), n 33 7 0.079
SVR = sustained virological response; SD = standard deviation; GT = genotype; RVR = rapid virological response; EVR = early virological response; FIB-4 = fibrosis index based on 4 factors; 
APRI = aspartate aminotransferase-to-platelet ratio index.
*On multivariate analysis EVR week 12 was found to be the only significant factor determining response, with a p-value of 0.004.
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with assessment of the utility of fibrosis scores, even though it was 
a retrospective single-centre study and did not include patients 
who had been treated with DAAs. However, this situation has since 
changed, and DAAs are going to be the standard of care for HCV 
patients in SA.
Conclusions
The current study concludes that genotype 5 is the predominant 
genotype in a single SA centre. It is more common than other 
genotypes among older SA blacks. Moreover, the APRI and FIB-4 
had sufficient power to diagnose advanced fibrosis in HCV patients, 
alleviating the need for liver biopsy in selected individuals. Despite 
their shared modes of transmission, hepatitis B and HIV infections 
were not commonly encountered in HCV patients in this cohort. 
Finally, EVR was found to determine who is likely to have an SVR.
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